Skip to main content
. Author manuscript; available in PMC: 2017 Sep 15.
Published in final edited form as: J Immunol. 2016 Aug 8;197(6):2509–2521. doi: 10.4049/jimmunol.1502659

Figure 2. Tumor antigen specific upregulation of GFP.

Figure 2

OVA tolerant POET mice were inoculated on the hind flanks with either MCA205 (WT) tumor cells or MCA205-OVA (OVA) expressing tumors. Ten days after tumor inoculation, OT-I/Thy1.1/Nur77GFP splenocytes were adoptively transferred into tumor bearing animals. A) Five days post adoptive transfer, OT-I T cells (identified by expression of Thy1.1 and their TCR alpha chain, Vα2) were isolated from the tumors. B) T cell activation markers were assessed on OT-I versus endogenous polyclonal CD8 T cells from WT (black dotted line, circles in bar graph) or OVA-expressing tumors (solid black line, squares in bar graph). Fold change was calculated from MFI of each activation marker on OTI T cells isolated from OVA expressing or WT tumors. Data are representative of 6 experiments with n=3–5 animals per treatment group per experiment. Unpaired two-tailed Student’s t test was used for statistical analysis and data represents mean with SD.